Ilona Reischl.
The Committee for Advanced Therapies (CAT) of the European Medicines Agency (EMA) chose at the January meeting to Ilona Reischl of the Austrian Agency for Medicines and Medical Devices (AGES MEA) as its new president for a three-year term. The new vice president will be elected at the February 16 meeting.
Prior to assuming this role, Reischl served as CAT’s Vice President for the past six years. This way, replaces Martina Schüssler-Lenzfrom the Paul-Ehrlich Institute (PEI) in Germany.
“I consider that the primary role of the CAT is to provide the expertise to ensure that safe and effective advanced therapy drugs are approved, for the benefit of patients,” Reichl explained. “In my role as chair, I will support CAT to contribute to the bigger picture and support European and international initiatives to facilitate the development, approval and access of these innovative products.”
Reischl started working with the European Medicines Regulatory Network in 2006 as a quality advisor. Later, created and directed the clinical division AGES MEA until 2018.
The function main of the CAT is to evaluate applications for advanced therapy medicinal products (ATMP) submitted to the EMA and draft an opinionbefore the Committee for Medicinal Products for Human Use (CHMP) adopts a final opinion on the marketing authorization of the medicine in question. It is also responsible for the classification and certification of ATMP, medicines for human use that are based on genes or cells. They offer new and innovative opportunities for the treatment of illnesses and injuries. The The role of the CAT includes the development of guidance documentsthe simplification of procedures, the training of evaluators and the organization of scientific workshops.
The information published in Redacción Médica contains affirmations, data and statements from official institutions and health professionals. However, if you have any questions related to your health, consult your corresponding health specialist.
